- Home
- MEGL vs INM Comparison
MEGL vs INM Comparison
Compare MEGL & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MEGL | INM |
|---|---|---|
| Founded | 2016 | 1981 |
| Country | Hong Kong | Canada |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 7.1M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MEGL | INM |
|---|---|---|
| Price | $0.65 | $1.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.5K | ★ 55.4K |
| Earning Date | 10-20-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.68 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,942,633.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $26.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.50 |
| 52 Week Low | $0.60 | $0.58 |
| 52 Week High | $1.64 | $2.33 |
Technical Indicators
Market Signals| Indicator | MEGL | INM |
|---|---|---|
| Relative Strength Index (RSI) | 15.73 | 50.30 |
| Support Level | N/A | $1.35 |
| Resistance Level | $1.35 | $1.40 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 11.60 | 36.14 |
Price Performance
Historical ComparisonAbout MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The company's offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.